Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
KIadis naar de €15,00 in november
Volgen
Denk dat de beweging vanmiddag hier mee te maken kan hebben. Als de uitkomt postief zou zijn, is dat schitterend nieuws voor Kiadis aangezien zij ook met de anti-CD19 werken. Lees vooral het vetgedrukte gedeelte. Decision vandaag dus. -------------------------------------------------www.onclive.com/web-exclusives/dramat... Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy Published Online: Wednesday, Sep 20, 2017 Print Button Sattva S. Neelapu, MD Sattva S. Neelapu, MD Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) significantly improved outcomes in refractory non-Hodgkin lymphoma (NHL) compared with standard therapies, a standardized analyses of 2 clinical trials showed. Three-fourths of patients treated with axi-cel achieved objective responses as compared with 20% of patients who received standard therapy. More than half of the axi-cel cohort had complete responses versus 6% of conventionally treated patients. Standardized survival analyses yielded a 6-month overall survival of 77% with axi-cell and 35% with conventional treatment for refractory NHL, Sattva Neelapu, MD, reported at the 2017 Society of Hematologic Oncology annual meeting. “Standardized analyses suggest that treatment with axi-cel in the ZUMA-1 trial yielded 8 to 10 times higher odds ratios for overall response and complete response, respectively, relative to currently available therapies,” Neelapu, associate professor of lymphoma and myeloma at MD Anderson Cancer Center, concluded in a poster presentation. “The estimated hazard ratio suggests an overall 77% reduction in the risk of death for patients treated with axi-cell in ZUMA-1 versus those treated with currently available therapies in the SCHOLAR-1 trial. Sensitivity analyses with ECOG performance status as a covariate yielded consistent results.” The ZUMA-1 study was the first multicenter pivotal trial of axi-cel (formerly KTE-C19) in patients with refractory, aggressive NHL. Initial results, reported earlier this year at the AACR annual meeting (abstract CT019), showed an 82% objective response rate, including complete responses in 54% of 101 patients. Based on data from ZUMA-1, the FDA granted a priority review to axi-cel in May 2017 for transplant-ineligible patients with relapsed or refractory NHL. Under the Prescription Drug User Fee Act, the FDA is scheduled to make its decision by November 29, 2017. SCHOLAR-1 was a pooled analysis of data for 635 patients with refractory, aggressive NHL treated with currently available therapies. The results showed low response rates and a 2-year survival of 20% (Blood. 2017;doi:10.1182/blood.2017.03.769620 [epub]). Neelapu and colleagues analyzed the ZUMA-1 data within the context of outcomes achieved with available therapies used in SCHOLAR-1, performing a comparative analysis that adjusted for imbalances in key covariates. The studies had balanced distribution of sex, disease type, and the proportion of patients with disease refractory to 2 consecutive lines of therapy. ZUMA-1 included more patients with 3 or more prior lines of therapy (69% vs 26%), with advanced (stage III-IV) disease (85% vs 67%), and less favorable IPI scores (=3, 48% vs 35%). More patients in ZUMA-1 had transformed follicular lymphoma or primary mediastinal large B-cell lymphoma (24% vs 4%), and more patients in SCHOLAR-1 had primary refractory disease (20% vs 2%). The patient population for SCHOLAR-1 comprised 2 phase III trials conducted at centers in the United States and Canada. Patients received available therapies for refractory NHL. Maximum follow-up for survival ranged from 7.6 to 14.8 years across participating centers. Patients in ZUMA-1 received the target dose of axi-cel (2 x 106 cells/kg) after low-dose conditioning with cyclophosphamide and fludarabine for 3 days. The modified intention-to-treat population involved 101 patients who received axi-cel. The trial had a median survival follow-up of 8.7 months. Standardized analyses included prespecified covariates selected for weighting: refractory disease status and whether a patient proceeded to stem-cell transplant after determination of refractory status. A sensitivity analysis incorporated ECOG performance status as a covariate for standardization. The primary analyses showed an objective response rate of 82% and complete responses in 54% of patients in the ZUMA-1 study, compared with 26% and 7% in SCHOLAR-1. The standardized comparison yielded an objective response rate of 74% and complete responses in 51% of patients versus 20% and 6% in SCHOLAR-1. The results for overall response rate translated into a standardized difference of 0.55 and an odds ratio of 7.97 in favor of ZUMA-1 (P <.0001). The results for complete response resulted in a standardized difference of 0.45 and an odds ratio of 10.2 in favor of ZUMA-1 (P <.0001). The median overall survival had yet to be reached for the ZUMA-1 cohort in either the primary analysis or standardized comparison. Medians for the SCHOLAR-1 study population were 6.3 and 3.9 months, respectively. The 6-month survival in the primary analyses was 80% in ZUMA-1 and 53% in SCHOLAR-1. The standardized comparison yielded 3-month survival of 93% for ZUMA-1 and 60% for SCHOLAR-1, and 6-month survival of 77% and 35% for ZUMA-1 and SCHOLAR-1, respectively (HR, 0.23; P <.0001).
Even verder gezocht en volgens mij is ZUMA-1 reeds approved in oktber 2017 door de FDA.
rider13 schreef op 29 november 2017 14:34 :
Klein deel van mijn aandelen verkocht om in cannabisaandelen te stoppen. Maar nog altijd een groot pakket Kiadis voor de longterm.
Welk cannabis aandeel heeft u gekocht als ik mag vragen?
aurora cannabis is één van de aandelen die ik bezit
DWB Happy schreef op 29 november 2017 12:57 :
[...]
...
Ik heb vandaag bijgekocht omdat ik een draai zie.
Ik zie, ik zie, wat jij niet ziet.
Bericht van 24 november.www.creative-biolabs.com/blog/car-t/l... There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives of patients. However, at the same time, the potential risks of CAR-T itself are also of concern to the industry as a category of innovative therapies. Recently, at the annual meeting of the Society of Cancer Immunotherapy (SITC), Dr. Mark Gilbert, chief medical officer of Juno Therapeutics, shared the results of JCAR015 therapy. Last year, more than one patient died in clinical trials, leaving the development of the therapy stalled. Nowadays, the experience and lessons learned from setbacks can be applied not only to the latest CAR-T therapy of Juno, but also to the whole field of CAR-T therapy. “We’ve always believed that many factors led to the results of clinical trials,” Dr. Gilbert said. “But we did not find these factors until now.” Dr. Gilbert refers to brain edema that occurs in clinical trials. As Dr. Stephan Grupp, another CAR-T therapeutics expert, says, “this symptom is totally unexpected”. The latest analysis of Juno indicates that these symptoms are associated with the excessive growth of CAR-T cells in which IL-15 plays a key role. This protein is an important growth factor for T cells. When the patient’s IL-15 levels are elevated, T cells will prematurely and rapidly expand. “We want to see CAR-T cells peak on the 11th, 12th and 14th days,” said Dr Gilbert. “That’s exactly what we saw in the TRANSCEND trial of JCAR017. In the JCAR015 ROCKET trial, cells were expanded to peak in seventh days in some patients, and such amplification was what we wanted to avoid. ” The analysis also shows that IL-15 levels are associated with the combination of fludaribine and cyclophosphamide. To this end, Juno configured a milder lymphocyte clearance program for the subsequent CAR-T trial. In the meantime, Juno is also trying a more personalized cell therapy: researchers will tailor a set of therapies based on the type of cancer, age, disease burden, antigen levels and other factors of the patient, for treatment. In this way, we can reduce the risk of premature CAR-T cell expansion. “It’s great that Juno can publish this information,” commented Dr. Grupp. For other companies developing CAR-T therapies, testing of patients’ IL-15 levels before treatment is also expected to improve the therapy safety. The insights that Juno draws from his painful experience are valuable assets for the entire field, and we are also looking forward to the JCAR017 on sale to benefit more patients.
Regelmatig post ik berichten zoals hierboven. Dit doe ik om met elkaar de ontwikkelingen bij te houden. Als dergelijke berichten/artikelen op dit forum gewaardeerd worden, ga ik hier graag mee door. kunnen jullie dit kenbaar maken door dit bericht te liken? Ik ga er graag mee door, maar alleen als daar behoefte aan is.
Ik had meer behoefte aan die uitbraak die je vandaag oreerde?
;-) ik zelf ook. Heb even gegoogled op CAR-t en de maand november; De hoeveelheid berichten geeft wel aan dat dit echt wel 'hot' is. Nu heb ik mijzelf nogmaals overtuigd om zeker te blijven zitten in Kiadis. Vandaag weer 1000 stuks bijgekocht. Even een korte stijging van en paar procent en dat niveau vasthouden zou inderdaad ook wel even mooi zijn. De dag is nog niet voorbij.
Voor nieuwe kopers: lees je goed in. Dit is een uitermate slecht verhandelbaar flutaandeel.
emergo schreef op 29 november 2017 16:06 :
Voor nieuwe kopers:
lees je goed in.
Dit is een uitermate slecht verhandelbaar flutaandeel.
Dat zeiden ze ook bij pharming. Maar blijf vooral weg van dit flutaandeel. Wij wachten rustig af op de goedkeuring, en gezien de lage free float is het dan zo goed als zeker dat mensen de boot gaan missen.
Ik hoop dat de nieuwe kopers er in stappen als er goed nieuws komt, dan stijgt de boel nog veel harder! Dus inderdaad wacht maar even af, totdat het flutaandeel een 'must-have' wordt.
Ik heb sinds februari Pharming.Ik kan dat elke minuut van de dag kopen of verkopen tegen koersen uit het orderboek. Kiadis is een flutaandeel. Altice is nog leuker als Kiadis. Ook daar kan je normaal handelen al zal ik het verder niemand aanbevelen.
Succes met Altice, gaat zo onder de 7 duiken.
Zat al paar keer onder de 7,00 maar je kan het verkopen wanneer je wilt. Kiadis dus niet.
emergo schreef op 29 november 2017 16:06 :
Voor nieuwe kopers:
lees je goed in.
Dit is een uitermate slecht verhandelbaar flutaandeel.
Gemiddeld dagvolume is op dit moment bijna 200K. 1 jaar geleden werd dat amper in 1 week gehaald. Een aandeel met een laag dagvolume is inderdaad niet geschikt voor een belegger met een KT horizon, zoiets moet je van te voren goed inschatten, anders kom je snel klem te zitten. Een beetje belegger neemt die zaken mee voordat hij in een aandeel stapt, dagvolumes en volaiteit. Het aandeel is goed, alleen dus niet geschikt voor jou, beleggen is vaak geduld leren hebben.
Sjedow schreef op 29 november 2017 14:55 :
[...]
Welk cannabis aandeel heeft u gekocht als ik mag vragen?
Ook aurora cannabis en ben nog een paar van die aandelen aan het volgen. Kan echt enorm stijgen de komende jaren!
Koersdoel ver hoging Het Kiadis Pharma- aandeel bereikte 0,36% tot 7,90 euro. De Amerikaanse makelaar Chardan begon de waarde te volgen met een aanbeveling om te "kopen". De richtprijs is vastgesteld op 19 euro, wat de meest optimistische mening is van analisten van Bloomberg.www.lecho.be/les-marches/homepage/Bio...
Chardan acted as Sole Bookrunner and Placement Agent for the Transaction. (verzorgde de laatste emissie)chardan.com/transactions/
Over de laatste emissie: Jefferies International Limited is acting as Sole Bookrunner and Canaccord Genuity Limited and Oppenheimer & Co. Inc. are acting as Lead Managers in connection with the Placing. Chardan and Saola Healthcare Partners are acting as financial advisors to the Company.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
864,86
-0,06%
EUR/USD
1,0677
+0,06%
FTSE 100
7.873,98
+0,33%
Germany40^
17.764,40
-0,03%
Gold spot
2.378,99
+0,76%
NY-Nasdaq Composite
15.683,37
-1,15%
Stijgers
Dalers